Cerus Corp (NASDAQ: CERS) is a medical technology company that develops and sells pathogen reduction systems for blood transfusion safety. Revenue comes primarily from the transactional sale of INTERCEPT Blood System processing kits to blood collection centers, supplemented by government development contracts. The INTERCEPT Blood System is sold to blood centers in the United States and internationally, with commercial operations in Europe managed through a wholly-owned subsidiary, Cerus Europe B.V., headquartered in the Netherlands. Additional revenue is generated through U.S. government contracts, including a $17.8 million agreement with the Department of Defense (amended through September 2028) for development of pathogen-reduced lyophilized cryoprecipitate, and a completed $11.1 million agreement with the FDA that ended in September 2025. The company also manufactures and sells INTERCEPT Fibrin Cryoprecipitate (IFC), produced in partnership with select blood centers. A joint venture targets commercialization in China. INTERCEPT processing kits are not directly reimbursable by governmental or commercial third-party payors in the U.S., making hospital adoption dependent on incorporation into existing reimbursement structures for blood products.

Revenue model

Transactional product revenue from INTERCEPT Blood System processing kit sales to blood collection centers; government contract revenue recognized as qualified direct costs are incurred on cost-reimbursement agreements with the FDA and Department of Defense; product revenue from INTERCEPT Fibrin Cryoprecipitate (IFC) sales.

Products and services

INTERCEPT Blood System (pathogen reduction processing kits for platelets, plasma, and red blood cells); INTERCEPT Fibrin Cryoprecipitate (IFC); pathogen-reduced lyophilized cryoprecipitate (Lyo-Cryo, in development under DoD contract); next-generation whole blood pathogen reduction compounds (developed under completed FDA contract).

Customers and end markets

Blood collection centers and blood banks (direct customers for INTERCEPT processing kits); hospitals (end users of INTERCEPT-treated blood products); U.S. federal government agencies including the FDA and Department of Defense (development contract counterparties); transfusion medicine end market.

Value-chain role

Medical device and biologic system supplier to blood collection centers; technology developer under government-funded research contracts; manufacturer and distributor of finished IFC product in partnership with select blood center manufacturers.

Geographic exposure

United States (primary commercial market, direct sales to blood centers); Europe and CIS countries (commercial operations via Cerus Europe B.V., headquartered in the Netherlands); China (joint venture for development and commercialization of blood transfusion products).

Source: SEC 10-K, filed 2026-03-02

Industry: Surgical & Medical Instruments & Apparatus Peers: ATRION CORP Avanos Medical Inc BioLife Solutions Inc Bioventus Inc Pulmonx Corp OrthoPediatrics Corp SmileDirectClub, Inc. Utah Medical Products Inc UFP Technologies Inc